BeOne Medicines Ltd.
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(c)
The following table describes for the quarterly period covered by this report each trading arrangement for the purchase or sale of Company securities adopted, modified orterminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement,” or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Chan Lee(Senior Vice President, General Counsel) | Adoption(May 14, 2025) | Rule 10b5-1 trading arrangement | Sale | August 13, 2026 | Up to 36,671 ADSs plus an additional number of ADSs subject to restricted share units (“RSUs”) equal to the net number of ADSs resulting from applicable RSU vestings after sell-to-cover for withholding tax. |
| Dr. Xiaobin Wu(President, Chief Operating Officer) | Modification(May 14, 2025) | Rule 10b5-1 trading arrangement | Sale | August 13, 2026 | Up to 89,794 ADSs. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.